Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro

Jack T. Nguyen, Justin D. Hoopes, Donald F. Smee, Mark N. Prichard, Elizabeth M. Driebe, David M. Engelthaler, Minh H. Le, Paul S Keim, R. Paul Spence, Gregory T. Went

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The recurring emergence of influenza virus strains that are resistant to available antiviral medications has become a global health concern, especially in light of the potential for a new influenza virus pandemic. Currently, virtually all circulating strains of influenza A virus in the United States are resistant to either of the two major classes of anti-influenza drugs (adamantanes and neuraminidase inhibitors). Thus, new therapeutic approaches that can be rapidly deployed and that will address the issue of recurring resistance should be developed. We have tested double and triple combinations of the approved anti-influenza drugs oseltamivir and amantadine together with ribavirin against three influenza virus strains using cytopathic effect inhibition assays in MDCK cells. We selected A/New Caledonia/20/99 (H1N1) and A/Sydney/05/97 (H3N2) as representatives of the wild-type versions of the predominant circulating seasonal influenza virus strains and A/Duck/ MN/1525/81 (H5N1) as a representative of avian influenza virus strains. Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations. This report demonstrates that a triple combination of antivirals was highly synergistic against influenza A virus. Importantly, the synergy of the triple combination was 2- to 13-fold greater than the synergy of any double combination depending on the influenza virus subtype. These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies.

Original languageEnglish (US)
Pages (from-to)4115-4126
Number of pages12
JournalAntimicrobial Agents and Chemotherapy
Volume53
Issue number10
DOIs
StatePublished - Oct 2009
Externally publishedYes

Fingerprint

Oseltamivir
Amantadine
Ribavirin
Orthomyxoviridae
Influenza A virus
Pandemics
Human Influenza
Antiviral Agents
Drug Antagonism
New Caledonia
Adamantane
Pharmaceutical Preparations
Madin Darby Canine Kidney Cells
Influenza in Birds
Ducks
Neuraminidase
Drug Combinations
Drug Interactions
In Vitro Techniques

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Infectious Diseases

Cite this

Nguyen, J. T., Hoopes, J. D., Smee, D. F., Prichard, M. N., Driebe, E. M., Engelthaler, D. M., ... Went, G. T. (2009). Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrobial Agents and Chemotherapy, 53(10), 4115-4126. https://doi.org/10.1128/AAC.00476-09

Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. / Nguyen, Jack T.; Hoopes, Justin D.; Smee, Donald F.; Prichard, Mark N.; Driebe, Elizabeth M.; Engelthaler, David M.; Le, Minh H.; Keim, Paul S; Spence, R. Paul; Went, Gregory T.

In: Antimicrobial Agents and Chemotherapy, Vol. 53, No. 10, 10.2009, p. 4115-4126.

Research output: Contribution to journalArticle

Nguyen, JT, Hoopes, JD, Smee, DF, Prichard, MN, Driebe, EM, Engelthaler, DM, Le, MH, Keim, PS, Spence, RP & Went, GT 2009, 'Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro', Antimicrobial Agents and Chemotherapy, vol. 53, no. 10, pp. 4115-4126. https://doi.org/10.1128/AAC.00476-09
Nguyen, Jack T. ; Hoopes, Justin D. ; Smee, Donald F. ; Prichard, Mark N. ; Driebe, Elizabeth M. ; Engelthaler, David M. ; Le, Minh H. ; Keim, Paul S ; Spence, R. Paul ; Went, Gregory T. / Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. In: Antimicrobial Agents and Chemotherapy. 2009 ; Vol. 53, No. 10. pp. 4115-4126.
@article{4bc0ce6ca71e488f965579981527f092,
title = "Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro",
abstract = "The recurring emergence of influenza virus strains that are resistant to available antiviral medications has become a global health concern, especially in light of the potential for a new influenza virus pandemic. Currently, virtually all circulating strains of influenza A virus in the United States are resistant to either of the two major classes of anti-influenza drugs (adamantanes and neuraminidase inhibitors). Thus, new therapeutic approaches that can be rapidly deployed and that will address the issue of recurring resistance should be developed. We have tested double and triple combinations of the approved anti-influenza drugs oseltamivir and amantadine together with ribavirin against three influenza virus strains using cytopathic effect inhibition assays in MDCK cells. We selected A/New Caledonia/20/99 (H1N1) and A/Sydney/05/97 (H3N2) as representatives of the wild-type versions of the predominant circulating seasonal influenza virus strains and A/Duck/ MN/1525/81 (H5N1) as a representative of avian influenza virus strains. Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations. This report demonstrates that a triple combination of antivirals was highly synergistic against influenza A virus. Importantly, the synergy of the triple combination was 2- to 13-fold greater than the synergy of any double combination depending on the influenza virus subtype. These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies.",
author = "Nguyen, {Jack T.} and Hoopes, {Justin D.} and Smee, {Donald F.} and Prichard, {Mark N.} and Driebe, {Elizabeth M.} and Engelthaler, {David M.} and Le, {Minh H.} and Keim, {Paul S} and Spence, {R. Paul} and Went, {Gregory T.}",
year = "2009",
month = "10",
doi = "10.1128/AAC.00476-09",
language = "English (US)",
volume = "53",
pages = "4115--4126",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "10",

}

TY - JOUR

T1 - Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro

AU - Nguyen, Jack T.

AU - Hoopes, Justin D.

AU - Smee, Donald F.

AU - Prichard, Mark N.

AU - Driebe, Elizabeth M.

AU - Engelthaler, David M.

AU - Le, Minh H.

AU - Keim, Paul S

AU - Spence, R. Paul

AU - Went, Gregory T.

PY - 2009/10

Y1 - 2009/10

N2 - The recurring emergence of influenza virus strains that are resistant to available antiviral medications has become a global health concern, especially in light of the potential for a new influenza virus pandemic. Currently, virtually all circulating strains of influenza A virus in the United States are resistant to either of the two major classes of anti-influenza drugs (adamantanes and neuraminidase inhibitors). Thus, new therapeutic approaches that can be rapidly deployed and that will address the issue of recurring resistance should be developed. We have tested double and triple combinations of the approved anti-influenza drugs oseltamivir and amantadine together with ribavirin against three influenza virus strains using cytopathic effect inhibition assays in MDCK cells. We selected A/New Caledonia/20/99 (H1N1) and A/Sydney/05/97 (H3N2) as representatives of the wild-type versions of the predominant circulating seasonal influenza virus strains and A/Duck/ MN/1525/81 (H5N1) as a representative of avian influenza virus strains. Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations. This report demonstrates that a triple combination of antivirals was highly synergistic against influenza A virus. Importantly, the synergy of the triple combination was 2- to 13-fold greater than the synergy of any double combination depending on the influenza virus subtype. These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies.

AB - The recurring emergence of influenza virus strains that are resistant to available antiviral medications has become a global health concern, especially in light of the potential for a new influenza virus pandemic. Currently, virtually all circulating strains of influenza A virus in the United States are resistant to either of the two major classes of anti-influenza drugs (adamantanes and neuraminidase inhibitors). Thus, new therapeutic approaches that can be rapidly deployed and that will address the issue of recurring resistance should be developed. We have tested double and triple combinations of the approved anti-influenza drugs oseltamivir and amantadine together with ribavirin against three influenza virus strains using cytopathic effect inhibition assays in MDCK cells. We selected A/New Caledonia/20/99 (H1N1) and A/Sydney/05/97 (H3N2) as representatives of the wild-type versions of the predominant circulating seasonal influenza virus strains and A/Duck/ MN/1525/81 (H5N1) as a representative of avian influenza virus strains. Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations. This report demonstrates that a triple combination of antivirals was highly synergistic against influenza A virus. Importantly, the synergy of the triple combination was 2- to 13-fold greater than the synergy of any double combination depending on the influenza virus subtype. These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies.

UR - http://www.scopus.com/inward/record.url?scp=70349331605&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349331605&partnerID=8YFLogxK

U2 - 10.1128/AAC.00476-09

DO - 10.1128/AAC.00476-09

M3 - Article

VL - 53

SP - 4115

EP - 4126

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 10

ER -